Achyut shareholders to swap into Zenith at 119-for-50 ratio

Tipsheet Editorial — Tue, 14 Jul 2026 21:19:50 GMT

Nano-cap API trader merges into WHO-certified manufacturer. Combined group could streamline operations, but deal awaits NCLT and shareholder approval.

What’s new

Board approved merger of Achyut Healthcare into Zenith Healthcare at 119:50 swap ratio.
Achyut holds ₹38.09 cr assets, ₹11.97 cr revenue; Zenith holds ₹10.99 cr assets, ₹10.94 cr revenue.
Deal aims to combine API trading with WHO cGMP-certified manufacturing under one entity.

Why it matters

This isn't a typical merger of equals. Achyut trades at a P/E of 607 with a 1.8% ROE. Its latest quarter: ₹4 crore sales, zero profit. The swap gives shareholders a stake in a certified manufacturer with export capability, effectively swapping a high-PE trading stock for a manufacturing business. The combined entity must prove it can generate the profits that justify the structure.

What we’re watching

NCLT and shareholder approval timelines.
Whether BSE issues a no-objection letter smoothly.
Post-merger financials: can the combined entity improve on Achyut's thin margins?

The full read

Achyut Healthcare, a nano-cap with a market cap of ₹192 crore, is merging into group entity Zenith Healthcare. The board approved a swap ratio of 119 Zenith shares for every 50 Achyut shares — 2.38 shares of a WHO cGMP-certified manufacturer for each share of what was largely an API trader. Achyut's financials are thin: ₹38.09 crore in assets, ₹11.97 crore in revenue. Zenith is slightly smaller at ₹10.99 crore and ₹10.94 crore. Combined, they would have assets of roughly ₹49 crore. The deal's logic is structural: replace a trading business with a manufacturing one. Yet Achyut's latest quarter tells a cautionary tale: sales of just ₹4 crore, net profit zero. The stock trades at a P/E of 607 and an ROE of 1.8%. This merger could change the business entirely or it could be a reshuffling of paper. Pending NCLT and shareholder approvals, the outcome hinges on whether the combined entity can produce sustainable profits.

Primary source: BSE · NSE

Achyut's revenue jumped 280%. Its profit fell.

Tipsheet Editorial — Wed, 27 May 2026 16:44:29 GMT

A nearly four-fold sales increase couldn't lift the bottom line. The company also raised ₹3.48 crore via new shares.

What’s new

FY26 revenue from operations surged 280% to ₹1,159.47 lakhs.
Net profit declined to ₹31.57 lakhs from ₹51.47 lakhs.
Company raised ₹3.48 crore via a preferential allotment of 58 lakh shares.

Why it matters

Achyut's top line grew nearly four-fold, but the bottom line contracted. Expenses and Ind AS accounting adjustments more than offset the revenue boom. The concurrent ₹3.48 crore capital raise dilutes shareholders at precisely the moment the business shows it can turn sales into profit.

What we’re watching

Whether the ₹3.48 crore raised gets deployed into higher-margin operations.
If the expense surge is a one-time scaling cost or a new baseline.
How Ind AS adoption affects reported earnings in coming quarters.

The full read

Achyut Healthcare's revenue grew 280% to ₹1,159.47 lakhs in FY26. Its profit shrank. Net profit fell to ₹31.57 lakhs from ₹51.47 lakhs. The company's expenses grew faster than its sales, and Ind AS accounting changes added another headwind. Separately, Achyut raised ₹3.48 crore by issuing 58 lakh new shares. That is a large capital raise for a business of this scale. The task now is to turn that capital, and the top-line growth, into profit. It isn't there yet.

Primary source: BSE · NSE

Achyut Healthcare Ltd. (ACHYUT) — Tipsheet

Achyut shareholders to swap into Zenith at 119-for-50 ratio

What’s new

Why it matters

What we’re watching

The full read

Achyut's revenue jumped 280%. Its profit fell.

What’s new

Why it matters

What we’re watching

The full read